Ian Mcconnell News
-
Amylin Pharmaceuticals Inc., maker of the diabetes drug Bydureon, may draw bids from other suitors after rejecting a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. earlier this year.
-
Male-pattern baldness may be caused by a protein in the scalp, according to research that raises the possibility drugs being tested by Merck & Co. and Actelion Ltd. for other uses might prevent hair loss.
-
The breakup of Abbott Laboratories into two companies will create a prescription-medicine spinoff that may become a $54 billion target for drugmakers looking to rejuvenate their flagging portfolios.
-
Fujifilm Holdings Corp. will buy two units of Merck & Co. that make biopharmaceuticals as it targets growth in the health-care industry to make up for declining sales in cameras and film.
-
Intercell AG fell the most in two weeks in Vienna trading after saying early data on whether its vaccine against a deadly hospital bug works may be delayed to the first or second quarter of 2011.
-
Kuwait Petroleum Corp. has shut its Europoort refinery in Rotterdam for maintenance, potentially limiting supplies of oil products at a time of declining stockpiles.
-
An Inspire Pharmaceuticals Inc. shareholder filed a lawsuit claiming Merck & Co. ’s $430 million offer for the company is inadequate.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page